Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933450 · ClinicalTrials.gov registry record · Phase 4
Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)
A Phase 4 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
NCT02933450 is a Phase 4 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 43 participants.
The verdict
NCT02933450, a Phase 4 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
Study Summary
The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25.2g of patiromer will be well tolerated in hyperkalemic patients in the Emergency Department setting. The FDA approved dosage of 25.2g is appropriate for this study because the research staff will enroll patients with moderate (K greater than 6 mEq/L) to severe hyperkalemia, and the higher dosage has typically been used in this population for more effective control.
Interventions
- DRUG Patiromer 25.2 g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02933450
The ClinicalTrials.gov registry entry for NCT02933450 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Patiromer 25.2 g is the first listed.
NCT02933450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02933450 about?
NCT02933450 is a clinical study titled "Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)". The Investigator hypothesize that a single dose of patiromer will lower serum potassium levels in less than 6hrs. Since a dosage of 30g/day for a period of 4 weeks has been studied in at least two multicenter randomized controlled trials, the Investigator further hypothesize that a single dose of 25...
What is the current status of trial NCT02933450?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2016-08. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02933450?
The interventions under investigation include: Patiromer 25.2 g (DRUG).
Who is sponsoring clinical trial NCT02933450?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.